Effects of Danazol on Clinical Improvement of Patients with Human T-cell Lymphotropic Virus Type I Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP): A Placebo-Controlled Clinical Trial

Overview

Journal Iran J Basic Med Sci

Publisher Mashhad University of Medical Sciences

Specialty General Medicine

Date 2014 Jan 29

PMID 24470864

Citations 1

Authors

Reza Boostani

Hamidreza Saber

Mohammadmahdi Etemadi

Affiliations

Soon will be listed here.

Abstract

Objective(s): Human T-Cell Lymphotropic Virus Type I (HTLV-I) associated myelopathy/tropical spastic paraparesis (HAM/TSP) is an endemic disease observed in Japan, Africa, Caribbean basin, and north-east Iran. It is usually presented as a chronic and progressive spastic paraparesis. There are some options for treatment of HAM/TSP patients. The aim of this study was to compare the effects of danazol controlled with placebo in relieving the symptoms and signs of HAM/TSP patients.

Materials And Methods: Among 77 patients with definite diagnosis of HAM/TSP based on clinical and para-clinical findings, 71 patients had the required criteria for entering the study. Severity of symptoms and the degree of motor disability were determined before the beginning of treatment based on motor disability grading (MDG) in both groups of patients and were followed during 6 months in 1 month intervals for changes in symptoms and their motor disabilities.

Results: Among 38 patients of the first group, after 6 months therapy with danazol, mean difference between MDG0 (before starting the treatment) and MDG6 (after six months), as an indicator of motor improvement in the patients, was 0.89. Meanwhile, among the 33 patients treated with identical appearing placebo, there was no significant difference between MDG0 and MDG6 (P< 0.001). Moreover, there was a significant difference in improvement of symptoms between two study groups.

Conclusion: This study showed that danazol provides relative effects on improving motor disabilities and symptoms of HAM/TSP patients that can be considered according to its lower side effects compared to other suggested treatments such as corticosteroids, and its lower costs in particular patients.

Citing Articles

Triple Therapy with Prednisolone, Pegylated Interferon and Sodium Valproate Improves Clinical Outcome and Reduces Human T-Cell Leukemia Virus Type 1 (HTLV-1) Proviral Load, Tax and HBZ mRNA Expression in Patients with HTLV-1-Associated....

Boostani R, Vakili R, Hosseiny S, Shoeibi A, Fazeli B, Etemadi M Neurotherapeutics. 2015; 12(4):887-95.

PMID: 26174324 PMC: 4604181. DOI: 10.1007/s13311-015-0369-3.

References

Nakagawa M, Nakahara K, Maruyama Y, Kawabata M, Higuchi I, Kubota H . Therapeutic trials in 200 patients with HTLV-I-associated myelopathy/ tropical spastic paraparesis. J Neurovirol. 1996; 2(5):345-55. DOI: 10.3109/13550289609146899. View

Mori H, Nakagawa M, Itoh N, Wada K, Tamaya T . Danazol suppresses the production of interleukin-1 beta and tumor necrosis factor by human monocytes. Am J Reprod Immunol. 1990; 24(2):45-50. DOI: 10.1111/j.1600-0897.1990.tb01037.x. View

Gelfand J, Sherins R, Alling D, Frank M . Treatment of hereditary angioedema with danazol. Reversal of clinical and biochemical abnormalities. N Engl J Med. 1976; 295(26):1444-8. DOI: 10.1056/NEJM197612232952602. View

Acien P, Shaw R, Irvine L, Burford G, Gardner R . CA 125 levels in endometriosis patients before, during and after treatment with danazol or LHRH agonists. Eur J Obstet Gynecol Reprod Biol. 1989; 32(3):241-6. DOI: 10.1016/0028-2243(89)90042-7. View

Agnello V, Pariser K, Gell J, Gelfand J, TURKSOY R . Preliminary observations on danazol therapy of systemic lupus erythematosus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol. 1983; 10(5):682-7. View

Ota H, Maki M, Shidara Y, Kodama H, Takahashi H, Hayakawa M . Effects of danazol at the immunologic level in patients with adenomyosis, with special reference to autoantibodies: a multi-center cooperative study. Am J Obstet Gynecol. 1992; 167(2):481-6. DOI: 10.1016/s0002-9378(11)91433-1. View

Gessain A, Gout O . Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med. 1992; 117(11):933-46. DOI: 10.7326/0003-4819-117-11-933. View

Mylvaganam R, Ahn Y, HARRINGTON W, Kim C . Immune modulation by danazol in autoimmune thrombocytopenia. Clin Immunol Immunopathol. 1987; 42(3):281-7. DOI: 10.1016/0090-1229(87)90016-x. View

Oh U, Jacobson S . Treatment of HTLV-I-associated myelopathy/tropical spastic paraparesis: toward rational targeted therapy. Neurol Clin. 2008; 26(3):781-97, ix-x. PMC: 2610848. DOI: 10.1016/j.ncl.2008.03.008. View

10.

Araujo A, Silva M . The HTLV-1 neurological complex. Lancet Neurol. 2006; 5(12):1068-76. DOI: 10.1016/S1474-4422(06)70628-7. View

11.

Ahn Y, HARRINGTON W, Mylvaganam R, AYUB J, Pall L . Danazol therapy for autoimmune hemolytic anemia. Ann Intern Med. 1985; 102(3):298-301. DOI: 10.7326/0003-4819-102-3-298. View

12.

Araujo A, Leite A, Lima M, Silva M . HTLV-1 and neurological conditions: when to suspect and when to order a diagnostic test for HTLV-1 infection?. Arq Neuropsiquiatr. 2009; 67(1):132-8. DOI: 10.1590/s0004-282x2009000100036. View

13.

Franssen A, van der Heijden P, Thomas C, Doesburg W, Willemsen W, Rolland R . On the origin and significance of serum CA-125 concentrations in 97 patients with endometriosis before, during, and after buserelin acetate, nafarelin, or danazol. Fertil Steril. 1992; 57(5):974-9. DOI: 10.1016/s0015-0282(16)55011-0. View

14.

Harrington Jr W, Sheremata W, Snodgrass S, Emerson S, Phillips S, Berger J . Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses. 1991; 7(12):1031-4. DOI: 10.1089/aid.1991.7.1031. View

15.

Schreiber A, Chien P, Tomaski A, Cines D . Effect of danazol in immune thrombocytopenic purpura. N Engl J Med. 1987; 316(9):503-8. DOI: 10.1056/NEJM198702263160903. View